Radiation Res & Translational Biology

项目总结(见说明)； 放射研究和翻译生物学(RRTB)计划的目标是通过1)设计和测试通过机制研究确定的新的分子靶点，2)解决肿瘤对治疗的耐药性和免疫监视的旁路，以及3)设计、评估和改进诊断、分期和为癌症患者提供治疗的技术，来改进联合放射治疗。计划成员 通过在生物化学、免疫学、药物设计、临床前模型和临床经验方面的多学科努力来解决这些目标，以加快从工作台到床边的转变。通过整合前癌症免疫学计划的成员，该计划得到了加强。目前的RRTB计划由来自11个部门的34名基础、翻译和临床研究人员组成，因此结合了基础和临床研究优势，进行从床到床的研究，并可以反向翻译临床数据，为进一步的翻译创新提供信息。这项工作得到了36位同行评审的支持 赠款，直接资金总额为1320万美元(NCI提供530万美元)。从2007年到2012年，计划成员出版的出版物总数为543份，其中11%是计划内出版物，22%是计划间出版物，4.6%是两者兼有。RRTB计划的具体研究主题是：(1)通过确定和表征电离辐射和联合治疗、疫苗开发和骨髓移植的分子靶标来改进RT治疗(2)免疫耐受性和免疫策略 监视系统。(3)肿瘤耐药：微环境、缺氧和血管生成。(4)正常组织保护：正常组织损伤/遗传毒性应激。(5)诊断和治疗创新的临床翻译；(6)改进临床实践：生物医学/生物信息学和比较有效性研究(CER)。该计划将以程序内和程序间的方式不断产生新的协作， 并与癌症中心的其他研究项目一起提供新的研究方向。

PROJECT SUMMARY (See instructions); The Radiation Research and Translational Biology, (RRTB) program goal is to improve combination radiation therapies by 1) designing and testing new molecular targets identified by mechanistic studies, and 2) addressing tumor resistance to therapy and bypass of immune surveillance, and 3) designing, assessing and improving technologies that diagnose, stage, and deliver therapies for cancer patients. Program members address these goals with multidisciplinary efforts in biochemistry, immunology, drug design, preclinical models, and clinical experience, to accelerate translation from bench to bedside. The Program has been strengthened by integration of members from the former Program in Cancer Immunology. The current RRTB program, comprised of 34 basic, translational and clinical investigators from eleven departments, thus combines basic and clinical research strengths to conduct bench to bedside research and can reverse translate clinical data to inform further translational innovations. This work is supported by 36 peer-reviewed grants totaling direct funds of $13.2 million ($5.3 million from NCI). The total number of publications generated by Program members from 2007 to 2012 is 543 of which 11% are Intra-programmmatic and 22% are Inter-programmatic, with 4.6% being both. The specific research themes ofthe RRTB Program are: (1) Improve RT therapies by defining and characterizing molecular targets for ionizing radiation and for combined therapies, vaccine development and BMT (2) Immune tolerance and strategies for immune surveillance. (3) Tumor resistance: Microenvironment, hypoxia and angiogenesis. (4) Protecting normal tissues: normal tissue injury/genotoxic stress. (5) Clinical translation of diagnostic and therapeutic innovations, and (6) Improving clinical practice: Biomedical/Bioinformatics and Comparitive Effectiveness Research (CER). This program will continually generate new collaborations, intra- and interprogrammatically, and fresh research directions with other research programs in the cancer center.